북미의 실험동물의학 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 동물 모델별, 용도별, 고객별, 국가별, 부문별 예측(2026-2033년)

North America Laboratory Animal Medicine Market Summary

The North America laboratory animal medicine market size was estimated at USD 3.40 billion in 2025 and is projected to reach USD 5.18 billion by 2033, growing at a CAGR of 5.48% from 2026 to 2033. The market growth is driven by the expansion of public diagnostic and surveillance laboratory networks, capital investment in animal health R&D and regulated laboratory infrastructure, tightening animal care standards and oversight expectations, and growth in applied research areas that still depend on in vivo models.

Capital investment in animal health R&D and regulated laboratory infrastructure is one of the crucial dynamic drivers for the sector growth. Large, multi-year investments in biologics manufacturing and research facilities expand production capacity and upstream preclinical and validation activity. New R&D laboratories integrated within manufacturing campuses increase the volume of in vivo studies required for formulation testing, stability work, and regulatory submissions. For instance, in May 2025, Merck Animal Health announced USD 895 million expansion of its De Soto, Kansas, biologics manufacturing facility. Such activities are bringing sustained demand for veterinary oversight, health monitoring, and compliant animal housing.

The path towards highly regulated, GLP-certified laboratories is further amplifying this growth. Certification raises expectations for data integrity, traceability, and repeatability, thereby enabling tighter control over animal health variables. For instance, in July 2025, Chalk River Laboratories (CRL) became Canada's first GLP-certified lab capable of radioactive work and pre-clinical radiopharmaceutical studies, following a Standards Council of Canada audit that adhered to OECD standards for regulators such as Health Canada and the FDA. Facilities operating under GLP standards require more frequent diagnostics, standardized preventive care protocols, and documented welfare outcomes. This increases healthcare intensity per animal rather than depending on simple growth in animal numbers.

Another important driver for the market is the expansion of public diagnostic and surveillance laboratory networks. This dynamic has been increasing the scale, intensity, and regularity of laboratory animal healthcare activities. Governments are building permanent diagnostic capacity for detecting animal diseases, evaluating vaccines, and conducting safety investigations. This has raised expectations for continuous health monitoring, standardized diagnostics, and documented veterinary oversight across laboratory animal populations. As laboratories become connected through formal networks, testing protocols and quality requirements are becoming more uniform. This drives higher testing frequency per animal, broader use of confirmatory diagnostics, and longer health-monitoring timelines. Animal health data is now generated on a routine basis rather than only during acute events. That change increases demand for diagnostic reagents, skilled veterinary staff, and compliant animal housing systems that support biosecure operations.

North America Laboratory Animal Medicine Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the NA laboratory animal medicine market report based on product, animal model, application, customer, and country:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics & Health Surveillance Products
  • Serology & PCR Test Kits
  • Microbiology & Parasitology Assays
  • Clinical Chemistry & Hematology Reagents / Panels
  • Others
• Therapeutics & Preventive Medicines
  • Vaccines
  • Anti-infectives (Antibiotics, Antivirals, Antifungals)
  • Antiparasitics (Endo- & Ecto-parasite Control)
  • Analgesics & Sedatives
  • Anesthetics
  • Anti-inflammatory & Supportive Care Drugs
  • Others
• Clinical Care Devices & Equipment
  • Animal Patient Monitoring Devices
  • Anesthesia Machines & Vaporizers
  • Ventilators & Respiratory Support Systems
  • Infusion & Syringe Pumps
  • Clinical Imaging & Diagnostic Devices
  • Others
• Clinical & Welfare Consumables
  • Needles, Syringes, Catheters & Vascular Access Sets
  • Bandages, Wound Care & Surgical Consumables
  • Disinfectants, Detergents & Sanitation Products
  • Personal Protective Equipment (PPE) & Barrier Consumables
  • Others
• Others Products
• Animal Model Outlook (Revenue, USD Million, 2021 - 2033)
• Rodents
• Rabbits
• Non-Human Primates (NHPs)
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Disease Surveillance & Colony Health Monitoring
• Preventive Care & Biosecurity
• Perioperative Care (Anesthesia, Analgesia, Surgical Support)
• Chronic Disease Management & Supportive Care
• Welfare & Behavioral Assessment
• End-of-Life & Euthanasia Management
• Training, Education & Compliance Support
• Others
• Customer Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Preclinical CROs & Contract Laboratories
• Academic & Research Institutions
• Others
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• U.S.
• Canada

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal Model
  • 1.2.3. Application
  • 1.2.4. Customer
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Bottom-Up Analysis
  • 1.7.2. Model 2: Volume-Pricing Analysis
  • 1.7.3. Model 3: Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Expansion Of Public Diagnostic And Surveillance Laboratory Networks
    • 3.2.1.2. Capital Investment In Animal Health R&D And Regulated Laboratory Infrastructure
    • 3.2.1.3. Strengthening Animal Care Standards And Oversight Expectations
    • 3.2.1.4. Growth In Applied Research Areas That Still Depend On In Vivo Models
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Policy Pressure To Reduce Or Replace Animal Testing
    • 3.2.2.2. Public Funding Uncertainty And Research Budget Cuts
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Value Chain Analysis
  • 3.3.1. Regulatory And Ethical Framework
  • 3.3.2. Upstream Inputs And Enabling Suppliers
  • 3.3.3. Product Development, Validation, And Manufacturing
  • 3.3.4. Regulatory And Compliance
  • 3.3.5. Distribution And Logistics
  • 3.3.6. Pharmaceutical And Biopharmaceutical End Users
  • 3.3.7. Preclinical Cros And Contract Laboratories
  • 3.3.8. Academic And Research Institutions
  • 3.3.9. Downstream Services, Lifecycle Management, And Value Capture
• 3.4. R&D Investment & Funding Landscape
  • 3.4.1. Pharmaceutical And Biopharmaceutical Internal R&D Investment
  • 3.4.2. Preclinical Cro Capital Allocation And Operational R&D
  • 3.4.3. Private Capital And Translational Funding Pathways
  • 3.4.4. Policy Direction, Ethical Priorities, And Funding Reallocation
• 3.5. Business Model Analysis
  • 3.5.1. OEM Go-To-Market Models
  • 3.5.2. Direct Sales Vs. Distributor / Dealer Models
  • 3.5.3. Bundled Offerings And Long-Term Supply Agreements
• 3.6. Pricing Analysis
• 3.7. Technology & Practice Landscape
  • 3.7.1. Diagnostics And Health Surveillance Products
  • 3.7.2. Therapeutics And Preventive Medicines
  • 3.7.3. Clinical Care Devices And Equipment
  • 3.7.4. Clinical And Welfare Consumables
  • 3.7.5. Other Supporting Technologies And Operational Systems
• 3.8. Customer Types and Buying Behavior Analysis
  • 3.8.1. Large Pharmaceutical And Biotechnology Companies
  • 3.8.2. Contract Research Organizations (CROs)
  • 3.8.3. Academic Research Institutions And Teaching Hospitals
  • 3.8.4. Government And National Research Laboratories
• 3.9. Role of Laboratory Animal Medicine in Preclinical Study Workflows
  • 3.9.1. Clinical Veterinary Care And Animal Welfare
  • 3.9.2. Study Design, Surgical Support, And Protocol Execution
  • 3.9.3. Facility Operations, Biosafety, And Regulatory Compliance
  • 3.9.4. Data Integrity, Quality Assurance, And Staff Training
• 3.10. Market Analysis Tools
  • 3.10.1. Porter's Five Forces Analysis
  • 3.10.2. PESTEL by SWOT Analysis

Chapter 4. North America Laboratory Animal Medicine Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. North America Laboratory Animal Medicine Market, By Product Movement Analysis
• 4.3. North America Laboratory Animal Medicine Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Diagnostics & Health Surveillance Products
  • 4.4.1. Diagnostics & Health Surveillance Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Serology & PCR Test Kits
    • 4.4.2.1. Serology & PCR Test Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Microbiology & Parasitology Assays
    • 4.4.3.1. Microbiology & Parasitology Assays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Clinical Chemistry & Hematology Reagents / Panels
    • 4.4.4.1. Clinical Chemistry & Hematology Reagents / Panels Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Therapeutics & Preventive Medicines
  • 4.5.1. Therapeutics & Preventive Medicines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Vaccines
    • 4.5.2.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Anti-infectives (Antibiotics, Antivirals, Antifungals)
    • 4.5.3.1. Anti-infectives (Antibiotics, Antivirals, Antifungals) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Antiparasitics (Endo- & Ecto-parasite Control)
    • 4.5.4.1. Antiparasitics (Endo- & Ecto-parasite Control) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Analgesics & Sedatives
    • 4.5.5.1. Analgesics & Sedatives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.6. Anesthetics
    • 4.5.6.1. Anesthetics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.7. Anti-inflammatory & Supportive Care Drugs
    • 4.5.7.1. Anti-inflammatory & Supportive Care Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.8. Others
    • 4.5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Clinical Care Devices & Equipment
  • 4.6.1. Clinical Care Devices & Equipment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Animal Patient Monitoring Devices
    • 4.6.2.1. Animal Patient Monitoring Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Anesthesia Machines & Vaporizers
    • 4.6.3.1. Anesthesia Machines & Vaporizers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Ventilators & Respiratory Support Systems
    • 4.6.4.1. Ventilators & Respiratory Support Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Infusion & Syringe Pumps
    • 4.6.5.1. Infusion & Syringe Pumps Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.6. Clinical Imaging & Diagnostic Devices
    • 4.6.6.1. Clinical Imaging & Diagnostic Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.7. Others
    • 4.6.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Clinical & Welfare Consumables
  • 4.7.1. Clinical & Welfare Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Needles, Syringes, Catheters & Vascular Access Sets
    • 4.7.2.1. Needles, Syringes, Catheters & Vascular Access Sets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. Bandages, Wound Care & Surgical Consumables
    • 4.7.3.1. Bandages, Wound Care & Surgical Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.4. Disinfectants, Detergents & Sanitation Products
    • 4.7.4.1. Disinfectants, Detergents & Sanitation Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.5. Personal Protective Equipment (PPE) & Barrier Consumables
    • 4.7.5.1. Personal Protective Equipment (PPE) & Barrier Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.6. Others
    • 4.7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Other Products
  • 4.8.1. Other Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Laboratory Animal Medicine Market: Animal Model Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. North America Laboratory Animal Medicine Market, By Animal Model Movement Analysis
• 5.3. North America Laboratory Animal Medicine Market Estimates & Forecasts, by Animal Model, 2021 to 2033 (USD Million)
• 5.4. Rodents
  • 5.4.1. Rodents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Rabbits
  • 5.5.1. Rabbits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Non-Human Primates (NHPs)
  • 5.6.1. Non-Human Primates (NHPs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others Animals
  • 5.7.1. Others Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Laboratory Animal Medicine Market: By Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. North America Laboratory Animal Medicine Market, By Application Movement Analysis
• 6.3. North America Laboratory Animal Medicine Market Estimates & Forecasts, By Application, 2021 to 2033 (USD Million)
  • 6.3.1. Disease Surveillance & Colony Health Monitoring
    • 6.3.1.1. Disease Surveillance & Colony Health Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Preventive Care & Biosecurity
    • 6.3.2.1. Preventive Care & Biosecurity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Perioperative Care (Anesthesia, Analgesia, Surgical Support)
    • 6.3.3.1. Perioperative Care (Anesthesia, Analgesia, Surgical Support) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Chronic Disease Management & Supportive Care
    • 6.3.4.1. Chronic Disease Management & Supportive Care Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.5. Welfare & Behavioral Assessment
    • 6.3.5.1. Welfare & Behavioral Assessment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.6. End-of-Life & Euthanasia Management
    • 6.3.6.1. End-of-Life & Euthanasia Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.7. Training, Education & Compliance Support
    • 6.3.7.1. Training, Education & Compliance Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.8. Others
    • 6.3.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Laboratory Animal Medicine Market: By Customer Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. North America Laboratory Animal Medicine Market, By Customer Movement Analysis
• 7.3. North America Laboratory Animal Medicine Market Estimates & Forecasts, by Customer, 2021 to 2033 (USD Million)
  • 7.3.1. Pharmaceutical & Biopharmaceutical Companies
    • 7.3.1.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Preclinical CROs & Contract Laboratories
    • 7.3.2.1. Preclinical CROs & Contract Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Academic & Research Institutions
    • 7.3.3.1. Academic & Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Others
    • 7.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Laboratory Animal Medicine Market: By Country Estimates & Trend Analysis

• 8.1. Country Market Dashboard
• 8.2. Country Market Share Analysis, 2025 & 2033
• 8.3. U.S
  • 8.3.1. Key Country Dynamics
  • 8.3.2. Competitive Scenario
  • 8.3.3. Regulatory Framework
  • 8.3.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Canada
  • 8.4.1. Key Country Dynamics
  • 8.4.2. Competitive Scenario
  • 8.4.3. Regulatory Framework
  • 8.4.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis Services LLC
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International GmbH
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Merck & Co., Inc.
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Dechra
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Elanco Animal Health
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Kent Scientific Corporation
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Harvard Apparatus
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Starr
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. QIAGEN
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Neogen Corporation
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Mediso Ltd.
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. IITCINC
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Thermo Fisher Scientific Inc.
    • 9.3.13.1. Participant's Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Product Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Plas-Labs, Inc.
    • 9.3.14.1. Participant's Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Product Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. TSE Systems
    • 9.3.15.1. Participant's Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Product Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. CH Technologies (USA), Inc
    • 9.3.16.1. Participant's Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Product Benchmarking
    • 9.3.16.4. Strategic Initiatives